Man Group PLC Vir Biotechnology, Inc. Transaction History

Man Group PLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$9.14 - $24.62 $2.6 Million - $6.99 Million	-283,929 Reduced 95.43%	13,598 $127,000
Q2 2023 Aug 14, 2023	SELL	$23.2 - $27.29 $730,660 - $859,471	-31,494 Reduced 9.57%	297,527 $7.3 Million
Q1 2023 May 15, 2023	BUY	$22.26 - $30.85 $5.82 Million - $8.07 Million	261,677 Added 388.57%	329,021 $7.66 Million
Q4 2022 Feb 14, 2023	SELL	$19.96 - $28.22 $1.87 Million - $2.65 Million	-93,895 Reduced 58.23%	67,344 $1.7 Million
Q3 2022 Nov 14, 2022	SELL	$18.26 - $31.1 $3.2 Million - $5.45 Million	-175,087 Reduced 52.06%	161,239 $3.11 Million
Q2 2022 Aug 15, 2022	BUY	$19.08 - $26.7 $3.24 Million - $4.54 Million	169,935 Added 102.13%	336,326 $8.57 Million
Q1 2022 May 16, 2022	BUY	$21.19 - $40.01 $2.32 Million - $4.39 Million	109,637 Added 193.18%	166,391 $4.28 Million
Q4 2021 Feb 14, 2022	BUY	$30.97 - $54.03 $1.35 Million - $2.35 Million	43,522 Added 328.91%	56,754 $2.38 Million
Q3 2021 Nov 15, 2021	BUY	$34.9 - $54.54 $182,317 - $284,916	5,224 Added 65.23%	13,232 $575,000
Q2 2021 Aug 16, 2021	BUY	$38.75 - $51.0 $26,931 - $35,445	695 Added 9.5%	8,008 $378,000
Q1 2021 May 17, 2021	SELL	$26.34 - $83.07 $258,606 - $815,581	-9,818 Reduced 57.31%	7,313 $375,000
Q4 2020 Feb 16, 2021	BUY	$25.51 - $43.38 $437,011 - $743,142	17,131 New	17,131 $458,000
Q3 2020 Nov 16, 2020	SELL	$28.28 - $53.6 $1.11 Million - $2.11 Million	-39,407 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$27.89 - $47.86 $1.1 Million - $1.89 Million	39,407 New	39,407 $1.62 Million

219

87.4M

127K

1.19M

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $922M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

Stay updated on Man Group PLC with notifications on news.